


Docket No. 00-721-US  
Serial No.: 09/828,276

### CLAIMS

1. (Previously presented) A compound of the formula:



R<sub>1</sub> and R<sub>2</sub> are each an amine group or an alkylamine group;

further wherein R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are each a hydrogen or a halogen;


further wherein R<sub>6</sub> is an alkyl alcohol group or a carboxamido group;

or a pharmaceutically acceptable salt thereof.


2. Cancelled.
3. Cancelled.
4. (Previously presented) The compound of Claim 1, wherein R<sub>1</sub> and R<sub>2</sub> each contain one to thirteen carbons.
5. Cancelled.

Docket No. 00-721-US  
Serial No.: 09/828,276

6. (Previously presented) The compound of Claim 1, wherein the amine group is on a terminal carbon.
7. (Previously presented) The compound of Claim 1, wherein said halogen is selected from the group consisting of fluorine, chlorine and bromine.
8. (Previously presented) The compound of Claim 1, wherein  $R_6$  is selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol and n-propyl alcohol.
9. (Original) The compound of Claim 1, wherein  $R_6$  is a N-alkylcarboxamido group selected from the group consisting of N-methylcarboxamido, N-ethylcarboxamido, N-isopropylcarboxamido, and N-n-propylcarboxamido.
10. (Previously presented) A compound of the formula:




wherein  $R_1$ ,  $R_2$ , are each:



$R_3$ ,  $R_4$ , and  $R_5$  are each hydrogen;

Docket No. 00-721-US  
Serial No.: 09/828,276

and R<sub>6</sub> is:




; or a pharmaceutically acceptable salt thereof.


11. Cancelled.
12. Cancelled.
13. Cancelled.
14. Cancelled.
15. Cancelled.
16. Cancelled.
17. Cancelled.
18. Cancelled.
19. Cancelled.
20. Cancelled.
21. (Previously presented) The compound of Claim 1, wherein said amine group is selected from the group consisting of primary amine, secondary amine and tertiary amine.

Docket No. 00-721-US  
Serial No.: 09/828,276

22. (Previously presented) The compound of Claim 1, wherein  $R_1$  and  $R_2$  are each:



23. (Previously presented) A pharmaceutical composition for the treatment of hypertension comprising an effective amount of a compound of the formula:



wherein  $R_1$  and  $R_2$  are each an amine group or an alkylamine group;  
further wherein  $R_3$ ,  $R_4$ , and  $R_5$  are each a hydrogen or a halogen;  
further wherein  $R_6$  is an alkyl alcohol group or a carboxamido group;  
or a pharmaceutically acceptable salt thereof;  
and a pharmaceutically acceptable carrier.

Docket No. 00-721-US  
Serial No.: 09/828,276

24. (Previously presented) The pharmaceutical composition of Claim 23, wherein  $R_1$  and  $R_2$  each contain one to thirteen carbons.
25. (Previously presented) The pharmaceutical composition of Claim 23, wherein said amine group is selected from the group consisting of primary amine, secondary amine and tertiary amine.
26. (Previously presented) The pharmaceutical composition of Claim 23, wherein said amine group is on a terminal carbon.
27. (Previously presented) The pharmaceutical composition of Claim 23, wherein said halogen selected from the group consisting of fluorine, chlorine and bromine.
28. (Previously presented) The pharmaceutical composition of Claim 23, wherein said alkyl alcohol group is selected from the group consisting of methyl alcohol, ethyl alcohol, isopropyl alcohol and n-propyl alcohol.
29. (Previously presented) The pharmaceutical composition of Claim 23, wherein  $R_6$  is a N-alkylcarboxamido group selected from the group consisting of N-methylcarboxamido, N-ethylcarboxamido, N-isopropylcarboxamido and N-n-propylcarboxamido.
30. (Previously presented) The pharmaceutical composition of Claim 23, wherein  $R_1$  and  $R_2$  are each:

